ACI’s 5th Annual Summit on Biosimilars – June 4-6, 2014

The American Conference Institute (“ACI”) will hold its 5th annual Summit on Biosimilars from June 5-6, 2014 at the InterContinental New York Barclay, New York, New York, and a pre-conference primer on June 4th with sessions titled “Biosimilars 101: Comprehensive Deep Dive Into the Relevant Legal, Regulatory, and Scientific Factors Companies Must Now” and “Biosimilars Around the World: A Regulatory and Patent Cheat Sheet to Maximize Global Biosimilars Market Share and Minimize Risk.”  During the main conference, attendees will hear from experts on myriad topics, including the latest on FDA’s implemention of the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), and recent litigation testing the BPCIA’s “patent dance” provisions (see our previous posts here and here). 

The Federal Trade Commission is slated to give a keynote address, titled “Revisiting Competition Issues in the Follow-On Biologics Arena: Substitution and Naming Conventions.”  And while we’re on those topics, we note that Hyman, Phelps & McNamara, P.C.’s Kurt R. Karst will moderate an industry round table on biosimilar naming and state substitutiuon legislation.  

A copy of the conference brochure is available here.  FDA Law Blog is able offer readers a special $200 discount off the current price tier for the conference.  The discount code is: FLB200.  We look forward to seeing you at the conference.